Obe-cel
Focused on delivering therapies for cancer and autoimmune disease
The CAR is designed to have a “fast-off” kinetic which mimics physiological T cell receptor interactions. Clinical trials of obe-cel have demonstrated that this enhanced kinetic profile results in increased T cell persistence leading to high levels of durable remissions and remarkably low levels of cytokine release syndrome and other immunotoxicities.
Autolus are applying extensive cell programming capability to develop product candidates across hematological malignancies, solid tumors and autoimmune disease.